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dilutions (1:10) of MBX-400. Lastly, infected cells were left untreated for
three days, upon addition of drug at 20.0 μM, the proviral load plateaued
throughout the remaining seven-day period. Therefore, it is acknowl-
edged that treatment of HHV-6B SUPT-1 infected cells with 20.0 μM of
2,2-bis-hydroxymethyl-cyclopropavir, MBX-400, inhibited proviral load
for both the supernatant and cell lysate. Further studies are being
conducted using the same model with HHV-6A. The sponsoring




Testing direct neuroprotective effects of current MS therapeutic
compounds with intravital two photon laser scanning microscopy
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Multiple sclerosis (MS) is a chronic, potentially highly disabling
autoimmune neurological disease that commonly affects young
adults. Neuronal injury is now considered a major part of MS
pathogenesis, but few of current therapies are directly targeting
neuronal disease mechanisms. It is conceivable, however, that
current as well as novel disease modifying drugs derive at least part
of their therapeutic action through direct neuroprotective effects.
Using intravital two photon laser scanning microscopy, our group
previously observed that lymphocyte-mediated long-term calcium
up-regulation, leading to dysfunction and eventually neuron death, is
partially reversible by NMDA receptor blockade. We presently
mimicked lymphocyte-induced excitotoxicity in neurons by applying
glutamate to live brain tissue of B6.thy1-TN-XXL mice, and measured
live calcium signaling in neurons using two-photon imaging.
Following glutamate exposure of 30 min, we applied therapeutic
drugs and determined neuro-/axonal calcium changes in vivo. We
have found that dimethyl fumerate (DMF), an effective MS treatment
that is supposed to exhibit both anti-inﬂammatory and neuropro-
tective function, decreases calcium signal intensity, while glutamate
increases it. DMF also decreased caspase 3/7 activity when directly
applied to primary cortical neurons in vitro. Other therapeutic
compounds, including Fingolimod, Laquinimod, Modaﬁnil, Fasudil and
Glibenclamide are currently being tested. These ongoing studies will
provide a comprehensive, inclusive overview of the direct neuro-
protective potential of current and novel MS therapeutics.
doi:10.1016/j.jneuroim.2014.08.598
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Background: To study the roles of Fasudil on macrophages, T cells and
TLR-4/NF-kappaB signaling pathway for the mechanisms underlying
the amelioration of EAE. Methods: Splenic encephalomyelitic mono-
nuclear cells (MNCs) from mice immunized with MOG35–55 on day 9
post-immunization were obtained and treated with/without Fasudil
in vitro for 72 h in the presence or absence of MOG35–55. We
analyzed the variances of macrophages phenotypes and T cell
subgroups by ﬂow cytometry, the expressions of iNOS, Arg-1, TLR-4
and p-NF-kappaB/p65 by Western blot, the production of NO by
Griess reaction, the levels of Arg-1 and cytokines by ELISA. Then
MNCs treated with/without Fasudil were resuspended at 5 × 107
cells in 500 μl PBS and transferred by intraperitoneal injection into
naïve C57BL/6 recipients. The body weight and clinical scores were
recorded every other day after EAE induction.
Results: MNCs treated in vitro with Fasudil declined the expression of
CD16/32 and IL-12 on F4/80-macrophages, but elevated the expression
of CD206, CD23 and IL-10 on F4/80-macrophages. Using western blot,
we found the level of iNOS was decreased and the level of Arg-1 was
enhanced in Fasudil-treated MNCs. Simultaneously, Fasudil inhibited
the production of NO and increased the concentration of Arg-1 in
cultured supernatants. Fasudil-primed MNCs showed the decreased
population of CD4+IFN-gamma+, CD4+IL-17+ and the increased
population of CD4+IL-10+, CD4+TGF-beta+. Moreover, the modulation
of Fasudil on T cells and macrophages was MOG-independent. In vitro
experiments indicate that p-NF-kappaB/p65 and inﬂammatory cyto-
kine TNF-alpha were inhibited in Fasudil-treated MNCs. The
experiment of adoptive transfer further displayed Fasudil-treated
encephalitogenic MNCs did not trigger the development of EAE, and
inhibited the expression of TLR-4/p-NF-kappaB/p65 and production of
inﬂammatory cytokine IL-1beta, IL-6 and TNF-alpha in spinal cord.
Conclusions: Fasudil is able to trigger inﬂammatory M1 macrophages
to anti-inﬂammatory M2 macrophages, converts encephalomyelitic T
cells to Tregs, inﬂuences TLR-4/p-NF-kappaB/p65 inﬂammatory
pathway, which in part deﬁnes that Fasudil has therapeutic potential
in EAE through regulating the polarization of macrophage and the
balance of immune cells during disease progression of EAE. This
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The ongoing success of dimethyl fumarate (DMF; Tecﬁdera) opens a
perspective for further development of the redox strategy in multiple
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sclerosis (MS) treatment. The mechanisms of anti-inﬂammatory and
neuroprotective effects of DMF involve the formation of adducts with
redox-sensitive thiol switches on the surface of T cell resulting in
suppressed activity, proliferation and pro-inﬂammatory cytokine re-
lease, and the activation of antioxidative defense in the central nervous
system (CNS) cells. Ethyl pyruvate (EP) appears to be a safer non-toxic
redox analogue of DMF, as they share common molecular targets. We
examined the effects of EP on CNS resident cells (astrocytes, microglia)
and encephalitogenic T cells, aswell as its inﬂuence on the clinical course
of actively induced experimental autoimmune encephalomyelitis (EAE).
Astrocytes and microglia were stimulated with pro-inﬂammatory
cytokines and treated with EP in vitro. Encephalitogenic immune cells
were isolated from draining lymph nodes of rats that were immunized
with myelin basic protein (MBP) and complete Freund's adjuvant (CFA)
and treated with EP in vivo. EP modulated cytokine generation in the
examined cells in an anti-inﬂammatory manner: (i) the production of
interleukin (IL)-6, but not IL-10, was down-regulated in astrocytes; (ii)
the release of IL-6, tumor necrosis factor and nitric oxide frommicroglial
cells was reduced; (iii) the production of interferon-gamma and IL-17,
but not IL-10, was suppressed in lymph node cells isolated from
MBP+ CFA-immunized rats. In addition, EP alleviated EAE course in
rats, delaying the onset, shortening the relapse, and lowering clinical
scores. These results imply that EP has a potency to inhibit inﬂammation
in the CNS. While further studies on the effect of EP on the CNS
inﬂammation are warranted, we believe that EPmight be applicable and
beneﬁcial in MS treatment.
doi:10.1016/j.jneuroim.2014.08.600
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Bangladesh has a number of aboriginal groups distributed throughout
the various hilly and forested regions of the country. Although some
degree ofmodernization is creeping in, the various aboriginals still rely on
their aboriginal medicinal practitioners (AMPs) for treatment of various
ailments. The AMPs usually administer various formulations of plants for
treatment of diseases. Because this practice has continued for centuries,
and because of the forested regions of the aboriginal habitats, the AMPs
have an extensive knowledge of plants and their speciﬁc uses. The studies
were conducted among the aboriginal medicinal practitioners of a large
Khyang group of people residing on the Chittagong Hill Tracts within
Bangladesh to gather information on plants used to treat various types of
mental health problems — a debilitating disease affecting millions of
people throughout the world. Aboriginal medicinal practitioners were
interviewed with the help of a semi-structured questionnaire and plant
specimens collected from the AMPs through guided ﬁeld-walks in which
the AMPs pointed out various plants and mentioned the uses for these
plants. The various plants used by the Khyang AMPs for treatment of
mental health problems included Abrus precatorius L., Achyranthes aspera
L.,Agaricus campestris L.,Aloe vera (L.) Burm.f.,Asparagus racemosusWilld.,
Bacopa monnieri (L.) Wettst., Calotropis gigantea (L.) Dryand., Cannabis
sativa L., Cinnamomum camphora (L.) J.Presl, Citrus aurantiifolia (Christm.)
Swingle, Cocos nucifera L., Geodorum densiﬂorum (Lam.) Schltr.,
Helichrysum luteoalbum (L.) Rchb., Ipomoea aquatica Forssk., Lawsonia
inermis L., Nicotiana tabacum L., Nigella sativa L., Ocimum gratissimum L.,
Oroxylum indicum (L.) Kurz, Plumbago indica L., Rauvolﬁa serpentina (L.)
Benth. ex Kurz, Santalum album L., Trichosanthes kirilowii Maxim., and
Zingiber ofﬁcinale Roscoe. It is concluded that the afore-mentioned plants
should be more thoroughly studied scientiﬁcally towards discovery of
anti-mental health problems principles, because modern medicine does
not have any absolute cure for mental health problems.
doi:10.1016/j.jneuroim.2014.08.601
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Dimethyl fumarate alters microglia phenotype and protects
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Haiyan Peng, Maria Matos, Brian T. Wipke, Moore H. Arnold,
Robert H. Scannevin
Neurology Research, Biogen Idec, Cambridge, MA, United States
Pathological activation of central nervous system (CNS) resident
microglia is considered to be a key factor in the progression of multiple
sclerosis (MS) and other neurodegenerative disorders. Activated
microglia can drive and propagate oxidative stress and proinﬂammatory
responses within the CNS, damaging sensitive cells such as neurons and
oligodendrocytes. Altering the phenotype of microglia, and subsequent
response to inﬂammatory stress, is a viable therapeutic approach toward
the reduction of neuroinﬂammation and an increase in the population of
potentially protective cells. Protection of CNS cells against toxic stress by
these means could ameliorate disease pathology.
Delayed-release dimethyl fumarate (DMF) is approved for the
treatment of MS in the United States, Canada, Australia and within
the European Union. The immunomodulatory and cytoprotective
properties of DMF have been described, however direct effects on
microglia and microglia-associated pathological actions have not
been well characterized.
Here we demonstrate that DMF can alter microglia inﬂammatory
responses by signiﬁcantly reducing proinﬂammatory cytokine and
chemokine production (IL-6, IL-12, TNF-alpha, RANTES and CCL5) in
primary cultures of rodent microglia after an inﬂammatory challenge.
These cytokines/chemokines are the same as those expressed at elevated
levels in the inﬂamed CNS of MS patients, suggesting that DMF could
exert a beneﬁcial anti-inﬂammatory effect. To assess the effect of DMF-
treated microglia on neuronal survival, conditioned media from
inﬂammatory-stimulated (lipopolysaccharide plus interferon gamma:
LPS + IFN-gamma) primary microglia cultures were treated with, or
without DMF then transferred onto naive primary cortical neurons. The
oxygen consumption rate (OCR) in the neurons was measured at 6 h
with an XF-96 analyzer (Seahorse Biosciences). Conditioned media
from microglia stimulated with LPS caused a reduction in basal OCR,
ATP production and maximal respiration in the recipient cortical
neurons. In contrast, mitochondria respiration was restored in
neurons that were incubated with conditioned media from
DMF + LPS stimulated microglia. These data demonstrate an
indirect protective effect of DMF on neurons via alteration of
microglia inﬂammatory responses.
These data provide evidence that DMF can modulate the inﬂam-
matory response in stimulated microglia and subsequently reduce
the toxicity of inﬂamed microglia on the neurons.
doi:10.1016/j.jneuroim.2014.08.602
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